Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia

Cancer Lett. 2015 Apr 28;360(1):28-38. doi: 10.1016/j.canlet.2015.01.039. Epub 2015 Jan 30.

Abstract

The fusion gene bcr-abl develops chronic myeloid leukemia (CML), and stimulates PI3K/Akt/mTOR signaling, leading to impaired autophagy. PI3K/Akt/mTOR signaling also plays an important role in cell metabolism. The Warburg effect is a well-recognized hallmark of cancer energy metabolism, and is regulated by the mTOR/c-Myc/hnRNP/PKM signaling cascade. To develop a new strategy for the treatment of CML, we investigated the associations among bcr-abl, the cascade related to cancer energy metabolism, and autophagy induced by a fatty-acid derivative that we had previously reported as being an autophagy inducer. Here we report that a fatty-acid derivative, AIC-47, induced transcriptional repression of the bcr-abl gene and modulated the expression profile of PKM isoforms, resulting in autophagic cell death. We show that c-Myc functioned as a transcriptional activator of bcr-abl, and regulated the hnRNP/PKM cascade. AIC-47, acting through the PPARγ/β-catenin pathway, induced down-regulation of c-Myc, leading to the disruption of the bcr-abl/mTOR/hnRNP signaling pathway, and switching of the expression of PKM2 to PKM1. This switching caused autophagic cell death through an increase in the ROS level. Our findings suggest that AIC-47 induced autophagic cell death through the PPARγ/β-catenin/bcr-abl/mTOR/hnRNP/PKM cascade.

Keywords: Autophagy; Bcr-abl; Cell death; Fatty-acid derivative; Warburg effect.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Autophagy / drug effects*
  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism*
  • Dose-Response Relationship, Drug
  • Energy Metabolism / drug effects
  • Fatty Acids / pharmacology*
  • Fusion Proteins, bcr-abl / genetics
  • Fusion Proteins, bcr-abl / metabolism*
  • Gene Expression Regulation, Neoplastic
  • Heterogeneous-Nuclear Ribonucleoproteins / metabolism
  • Humans
  • Isoenzymes
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism*
  • PPAR gamma / metabolism
  • Proto-Oncogene Proteins c-myc / genetics
  • Proto-Oncogene Proteins c-myc / metabolism
  • Pyruvate Kinase / genetics
  • Pyruvate Kinase / metabolism*
  • RNA Interference
  • Signal Transduction / drug effects
  • TOR Serine-Threonine Kinases / metabolism
  • Thyroid Hormone-Binding Proteins
  • Thyroid Hormones / genetics
  • Thyroid Hormones / metabolism*
  • Transcription, Genetic
  • Transfection
  • beta Catenin / genetics
  • beta Catenin / metabolism

Substances

  • Antineoplastic Agents
  • CTNNB1 protein, human
  • Carrier Proteins
  • Fatty Acids
  • Heterogeneous-Nuclear Ribonucleoproteins
  • Isoenzymes
  • MYC protein, human
  • Membrane Proteins
  • PPAR gamma
  • Proto-Oncogene Proteins c-myc
  • Thyroid Hormones
  • abl-bcr fusion protein, human
  • beta Catenin
  • MTOR protein, human
  • Pyruvate Kinase
  • Fusion Proteins, bcr-abl
  • TOR Serine-Threonine Kinases